{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=32", "query": { "condition": "Relapsed Lymphomas", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 2067, "total_pages": 207, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Lymphomas&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T19:50:52.702Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03696537", "title": "IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total Marrow Irradiation (TMI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Naoyuki G. Saito, M.D., Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2018-08-29", "completion_date": "2021-04-13", "has_results": false, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03696537" }, { "nct_id": "NCT00840853", "title": "Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)", "Chronic Lymphocytic Leukemia (CLL)", "Non Hodgkin's Lymphoma" ], "interventions": [ { "name": "CD19CAR/virus specific T cells", "type": "GENETIC" }, { "name": "Benadryl and Tylenol", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2009-04", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840853" }, { "nct_id": "NCT05366881", "title": "cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain Cancer", "Breast Cancer", "Bladder Cancer", "Cervical Cancer", "Colorectal Cancer", "Endometrial Cancer", "Esophageal Cancer", "Stomach Cancer", "Head and Neck Cancer", "Hepatobiliary Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cancer", "Sarcoma", "Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Adela, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 7000, "start_date": "2022-05-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 17, "location_summary": "Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "New Albany", "state": "Indiana" }, { "city": "Corbin", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05366881" }, { "nct_id": "NCT01165112", "title": "Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2010-09", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165112" }, { "nct_id": "NCT02593045", "title": "Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-Cell Lymphoma" ], "interventions": [ { "name": "IPH4102", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Innate Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2015-10", "completion_date": "2020-04", "has_results": false, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 2, "location_summary": "Stanford, California • Columbus, Ohio", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593045" }, { "nct_id": "NCT03179930", "title": "Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Relapsed", "Refractory" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-06-07", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 9, "location_summary": "Evanston, Illinois • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179930" }, { "nct_id": "NCT01321346", "title": "A Study Of Panobinostat In Children With Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute, Childhood", "Myelogenous Leukemia, Acute, Childhood", "Hodgkin's Disease", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "8 Years to 21 Years" }, "enrollment_count": 30, "start_date": "2011-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-11-24", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 20, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321346" }, { "nct_id": "NCT00217646", "title": "Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "Blastic Phase", "de Novo Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome" ], "interventions": [ { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217646" }, { "nct_id": "NCT01076270", "title": "Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "plerixafor", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2010-06", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076270" }, { "nct_id": "NCT05537766", "title": "Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Waldenstrom Macroglobulinemia", "Relapsed/Refractory Richter Transformation", "Relapsed/Refractory Burkitt Lymphoma", "Relapsed/Refractory Hairy Cell Leukemia" ], "interventions": [ { "name": "Brexucabtagene Autoleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2022-11-01", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-14T19:50:52.702Z", "location_count": 12, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537766" } ] }